Coronavirus disease 2019 in individuals with neuromyelitis optica and associated disorders

Takeaway

  • Individuals with neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) should remain on immunosuppressants to prevent severe relapse and are recommended to practice personal protective measures to reduce the risk of coronavirus disease 2019 (COVID-19) infections.

Why this matters ?

    There has been little information on how COVID-19 affects individuals with pre-existing neurological conditions such as NMOSD or MOGAD. Nearly all individuals with NMOSD are treated with immunosuppressive therapies which may alter the severity of the coronavirus infection. The results of this study increase the understanding of how individuals with NMOSD or MOGAD may be affected by a COVID-19 infection.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.